<DOC>
	<DOCNO>NCT02482272</DOCNO>
	<brief_summary>The purpose study compare efficacy safety continue Lamivudine plus Adefovir Adefovir versus switch Entecavir plus Adefovir patient LAM-resistant chronic hepatitis B suboptimal response Lamivudine plus Adefovir Adefovir</brief_summary>
	<brief_title>Compare Continuing Lamivudine Plus Adefovir Adefovir Versus Switching Entecavir Plus Adefovir Patients With LAM-resistant Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Chronic hepatitis B Age ≥ 20 year old Currently take Lamivudine Adefovir combination therapy Adefovir monotherapy chronic HBV infection 24 week Proven Lamivudine resistant mutation HBV DNA level screen ≥ 15 IU/mL Females must postmenopausal , unable conceive , test negative pregnancy via urine test Patient able give write informed consent prior study start comply study requirement A history current decompensated cirrhosis hepatocellular carcinoma Currently receive antiviral , immunomodulatory , cytotoxic corticosteroid therapy Coinfected HCV HIV A history organ transplantation Pregnant breastfeeding Current clinically relevant abuse alcohol drug . Significant immunocompromised , gastrointestinal , renal ( serum creatinine ≥ 1.5 mg/dL ) , hematological , psychiatric , bronchopulmonary , biliary disease exclude asymptomatic GB stone , neurological , cardiac , oncologic , allergic disease medical illness investigator 's opinion might interfere therapy malignancy previous 5 year</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>